2006
DOI: 10.1001/archderm.142.12.1591
|View full text |Cite
|
Sign up to set email alerts
|

Phenotype, Genotype, and Sustained Response to Anakinra in 22 Patients With Autoinflammatory Disease Associated With CIAS-1/NALP3 Mutations

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
124
0
10

Year Published

2009
2009
2015
2015

Publication Types

Select...
7
2
1

Relationship

1
9

Authors

Journals

citations
Cited by 177 publications
(142 citation statements)
references
References 23 publications
8
124
0
10
Order By: Relevance
“…Approximately three quarters of patients with milder disease give a family history of similar symptoms. 11,12 The most severe disease, known as chronic infantile neurological cutaneous and articular syndrome (CINCA) or neonatal onset multisystem infl ammatory disorder (NOMID), is usually due to de novo mutation. NLPR3 is a key component of the infl ammasone, an intracellular platform which regulates the production of IL-1 beta.…”
Section: Cryopyrin-associated Periodic Syndromementioning
confidence: 99%
“…Approximately three quarters of patients with milder disease give a family history of similar symptoms. 11,12 The most severe disease, known as chronic infantile neurological cutaneous and articular syndrome (CINCA) or neonatal onset multisystem infl ammatory disorder (NOMID), is usually due to de novo mutation. NLPR3 is a key component of the infl ammasone, an intracellular platform which regulates the production of IL-1 beta.…”
Section: Cryopyrin-associated Periodic Syndromementioning
confidence: 99%
“…Se comenzó a emplear por primera vez para el CAPS en el año 2003, y ha demostrado su eficacia en el FCAS y SMW, y no en todos los casos de NOMID. Puede reducir la proteinuria y estabilizar los niveles de creatinina 32 , se desconoce su impacto en la hipoacusia, aunque en algunos casos se ha detectado una recuperación parcial. Probablemente esto dependa del momento de inicio del tratamiento y si, cuando se inicia, ya hay daño irreversible 33 .…”
Section: Monitorización De La Respuesta Al Tratamientounclassified
“…Further, the effect of etanercept on SAA in 92 patients with ankylosing spondylitis (AS) reportedly reduced the median pre-treatment level of 4.8 mg/L to 0.9 after 1 month and to 0. (Leslie et al, 2006) and from a mean level of 645 mg/L to 3.4 mg/L in 5 patients with tumor necrosis factor-associated periodic syndrome (TRAPS) (Gattorno et al, 2008). Anakinra thus appears to be highly effective for the suppression of SAA levels in patients with autoinflammatory diseases but there have been no reports on whether anakinra can also inhibit serum concentrations of SAA in patients with inflammatory arthritides.…”
Section: The Inhibitory Effect Of Tocilizumab and Other Biologics On mentioning
confidence: 99%